By Karim Rahemtulla A few weeks ago, I noticed a large insider buy at AbbVie (NYSE: ABBV), the giant pharmaceutical company that sells best-of-class drugs like Humira. It caught my eye, as the buy was for more than $1 million.
But that was not enough for me to issue a buy alert to War Room members.
One insider buy doesn’t represent anything unless it’s followed up by more buying from other insiders, especially officers of the company.
When only one insider buys shares, even if he or she makes multiple purchases, it’s not a good indication of anything more than faith in the company and a …read more
